BioCentury
ARTICLE | Clinical News

ABX464: Phase IIa data

January 18, 2016 8:00 AM UTC

Top-line data from the double-blind, placebo-controlled, dose-escalation, Mauritian Phase IIa ABX464-003 trial in about 80 treatment-naive patients with HIV infection showed that once-daily 150 mg ora...